Global Circulating Tumor Cell (CTC) Testing Market


Circulating Tumor Cell (CTC) Testing Market Outline

Circulating Tumor Cell (CTC) Testing is a simple blood test which helps oncologists to assess the prognosis of patients with metastatic colorectal, breast or prostate cancer. The cell search test is the only FDA approved test for CTC assessment. CTC’s are the cancer cells that detach from solid tumors and enter the blood stream.


Circulating Tumor Cell (CTC) Testing Market Dynamics

Increasing in number of cancer cases and rise in geriatric population are the major factors which are attributing for the growth of the circulating tumor cell (CTC) testing market globally. As per the WHO statistics cancer accounts for 13% of deaths globally every year, moreover 70% increase in cancer incidences is anticipated over the next couple of decades and global geriatric population is anticipated to nearly double from 12% to 22% from 2015 to 2022. Furthermore, advanced technologies in circulating tumor cell (CTC) testing, improved healthcare expenditure, growing awareness regarding circulating tumor cell (CTC) testing and increased government support are the few more factors which are boosting the growth of circulating tumor cell (CTC) testing market globally. However, stringent regulatory framework, prolonged time of approvals for product launching and cost containment measures are the few factors restraining the growth of circulating tumor cell (CTC) testing market globally.


Market Scope: 

Circulating Tumor Cell (CTC) Testing market is segmented based on the technology, application, end user and geographical regions


Based on the Technology, Global Market is segmented into the following

  • CTC Detection
    • Functional in-vitro cell invasion assay
    • Molecular(RNA) based technologies
    • Xenotransplantation models
    • Immunocytochemical technologies
    • EPISPOT functional in-vitro cell culture
  • CTC Enrichment
    • Microchips
    • In-vivo positive selection
    • Single spiral micro channel
    • Ex-vivo positive selection
    • Negative selection
  • CTC Analysis


Based on the Application,Global Market is segmented into the following

  • EMT biomarkers development
  • Cancer stem cell research
  • Tumorigenesis research
  • Others


Based on the end user, Global Market is segmented into the following

  • Diagnostic Centers
  • Hospitals
  • Ambulatory Surgical Centers


Based on the geographical regions, Global Market is segmented into the following

  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • The Middle East and Africa


Market Summary: 

Global market is highly fragmented with small biotech firms holding a chunk of the overall industry share. CTC are very rare that an average only 1 CTC is present in 1 billion blood cells and CTC clusters are even rarer. Recent development of cluster chip has been successful in capturing CTC clusters ranging between 2-17 cells is an important development in the global market. According to WHO, cancer incidence is projected to rise by 50% to reach 15 million by the end of this decade. This alarming increase in a number of patients necessitates this as a potential treatment approach addressing the growing global burden of the disease. Biotech firms dominate the global circulating tumor cell (CTC) testing market. The players are constantly engaged in R&D in order to develop novel methods to treat cancers. Favorable government initiatives will fuel global circulating tumor cell (CTC) testing market size. For instance, CDC supports nationwide screening programs for control of breast, cervical and colorectal cancer among low-income women with little or no health insurance.


Regional Analysis:  

Geographically, global market is segmented into North America, Europe, Asia Pacific, Latin America, and Middle East and Africa. North America dominates the global market for due to a large number of aging population and technological advancement in the region, heavy investments in R & D activities along with government support will boost the industry demand over the coming years. The UK market is anticipated to grow rapidly over the forecast timeline due to the rising occurrence of cancer along with increasing acceptance of advanced technology. Asia is expected to witness high growth in circulating tumor cell (CTC) testing market, due to increasing government initiatives, rising economy, and improvement in healthcare infrastructure in the region. Some of the key driving forces for circulating tumor cell (CTC) testing market in emerging countries are increasing R&D investment, a large pool of patients and rising government funding.


Competition Assessment:Circulating Tumor Cell (CTC) Testing market

  • Fluxion Biosciences (U.S.),
  • Clearbridge BioMedics (Singapore)
  • Adnagen (Germany), Apocell (U.S.)
  • Advanced Cell Diagnostics (U.S.)
  • Cynvenio Biosystems (U.S.)
  • Aviva Biosciences (U.S.)
  • Biocept Inc. (U.S.)
  • Canopus Biosciences (U.S.)
  • Biofluidica (U.S.)


Key Features of the Report:

  • The report provides granular level information about the market size, regional market share, historic market (2015-2019) and forecast (2020-2026)
  • The report covers in-detail insights about the competitor’s overview, company share analysis, key market developments, and their key strategies
  • The report outlines drivers, restraints, unmet needs, and trends that are currently affecting the market
  • The report tracks recent innovations, key developments and startup’s details that are actively working in the market
  • The report provides plethora of information about market entry strategies, regulatory framework and reimbursement scenario
  • The report analyses the impact of the socio-political environment through PESTLE Analysis and competition through Porter’s Five Force Analysis in addition to recent technology advancements and innovations in the market



PBI Location Map


Precision Business Insights, 5th Floor, Mohan’s Elite, Opp : Bharat Petroleum Pump, Khanamet Road, Hitech City, Hyderabad – 500084


Precision Business Insights, Kemp House, 152 – 160 City Road, London EC1V 2NX